Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of weekly Marqibo in adults with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia
2006-006978-20Phase 2Completed
- Sponsor
- Talon Therapeutics , Inc.
- Start
- Aug 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine in acute lymphoblastic leukemia (ALL), sponsored by Talon Therapeutics , Inc. Primary endpoint: Complete remission plus complete remission with incomplete blood count recovery. Started Aug 2007; status: completed.
02
Drugs
vincristine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2006-006978-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006978-20.